

PC/CA 2004 / 000033

23

MARCH 2004 23.03.04

REC'D 21 APR 2004

WIPO

PCT

PA 1142909

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 10, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.


APPLICATION NUMBER: 60/460,397

FILING DATE: April 07, 2003

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. SWAIN
Certifying Officer

Best Available Copy

60460397, 040703

PTO/SB/16 (10-01)
Approved for use through 10/31/2002, OMB 0551-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No.

| INVENTOR(S) | | | | | |
|---|------------------------|---|---------|--|---------|
| Given Name (first and middle [if any]) | Family Name or Surname | Residence (City and either State or Foreign Country) | | | |
| STUART A. YICHENG | BERGER ZHANG | TORONTO, ONTARIO, CANADA TORONTO, ONTARIO, CANADA | | | |
| <input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto | | | | | |
| TITLE OF THE INVENTION (280 characters max) | | | | | |
| PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING MULTIDRUG RESISTANT CANCER | | | | | |
| CORRESPONDENCE ADDRESS | | | | | |
| Direct all correspondence to: | | | | | |
| <input type="checkbox"/> Customer Number | | | | Place Customer Number Bar Code Label here | |
| OR | | Type Customer Number here | | | |
| <input checked="" type="checkbox"/> Firm or Individual Name | | STUART A. BERGER | | | |
| Address | | 220 Strathearn Road | | | |
| Address | | | | | |
| City | Toronto | State | Ontario | ZIP | M6C 1S4 |
| Country | Canada | Telephone | | Fax | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | | | |
| <input checked="" type="checkbox"/> Specification Number of Pages | | 28 | | <input type="checkbox"/> CD(s), Number | |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets | | 7 | | <input type="checkbox"/> Other (specify) | |
| <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 | | | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT | | | | | |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. | | | | | |
| <input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees | | | | | |
| <input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: | | | | FILING FEE AMOUNT (\$) | |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. | | | | 80.00 | |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. | | | | | |
| <input checked="" type="checkbox"/> No. | | | | | |
| <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____ | | | | | |

Respectfully submitted,
SIGNATURE

Stuart Berger

Date Jan 21, 2003

TYPED or PRINTED NAME

STUART A. BERGER

REGISTRATION NO.
(if appropriate)

Docket Number:

TELEPHONE

416-946-6541

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27.

TOTAL AMOUNT OF PAYMENT (\$) 80.00

Complete if Known

| | |
|----------------------|------------------|
| Application Number | |
| Filing Date | |
| First Named Inventor | Stuart A. Berger |
| Examiner Name | |
| Art Unit | |
| Attorney Docket No. | |

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None
☐ Deposit Account

Deposit Account Number: _____
Deposit Account Name: _____

The Commissioner is authorized to: (check all that apply)
☒ Charge fee(s) indicated below ☐ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☒ Charge fee(s) indicated below, except for the filing fee, to the above identified deposit account.

FEE CALCULATION

| 1. BASIC FILING FEE | | Fee Description | Fee Paid |
|------------------------|------------------------|------------------------|----------|
| Large Entity Code (\$) | Small Entity Code (\$) | | |
| 1001 750 | 2001 375 | Utility filing fee | |
| 1002 330 | 2002 165 | Design filing fee | |
| 1003 520 | 2003 260 | Plant filing fee | |
| 1004 750 | 2004 375 | Reissue filing fee | |
| 1005 460 | 2005 230 | Provisional filing fee | 80.00 |
| SUBTOTAL (1) | | | 80.00 |

| 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE | | Fee Description | Fee Paid |
|---|------------------------|---|----------|
| Large Entity Code (\$) | Small Entity Code (\$) | | |
| 1202 18 | 2202 9 | Claims in excess of 20 | |
| 1201 84 | 2201 42 | Independent claims in excess of 3 | |
| 1203 280 | 2203 140 | Multiple dependent claim, if not paid | |
| 1204 84 | 2204 42 | Reissue independent claims over original patent | |
| 1205 18 | 2205 9 | Reissue claims in excess of 20 and over original patent | |
| SUBTOTAL (2) | | | 0 |

*or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)

| 3. ADDITIONAL FEES | | Fee Description | Fee Paid |
|----------------------------------|------------------------|--|----------|
| Large Entity Code (\$) | Small Entity Code (\$) | | |
| 1051 130 | 2051 65 | Surcharge - late filing fee or oath | |
| 1052 50 | 2052 25 | Surcharge - late provisional filing fee or cover sheet | |
| 1053 130 | 2053 65 | Non-English specification | |
| 1812 2520 | 2812 1260 | For filing a request for <i>ex parte</i> reexamination | |
| 1804 920 | 2804 460 | Requesting publication of SIR prior to Examiner action | |
| 1805 1840 | 2805 920 | Requesting publication of SIR after Examiner action | |
| 1251 110 | 2251 55 | Extension for reply within first month | |
| 1252 210 | 2252 105 | Extension for reply within second month | |
| 1253 310 | 2253 155 | Extension for reply within third month | |
| 1254 410 | 2254 205 | Extension for reply within fourth month | |
| 1255 510 | 2255 255 | Extension for reply within fifth month | |
| 1401 160 | 2401 80 | Notice of Appeal | |
| 1402 160 | 2402 80 | Filing a brief in support of an appeal | |
| 1403 280 | 2403 140 | Request for oral hearing | |
| 1451 1510 | 2451 755 | Petition to institute a public use proceeding | |
| 1452 110 | 2452 55 | Petition to revive - unavoidable | |
| 1453 1300 | 2453 650 | Petition to revive - unintentional | |
| 1501 1900 | 2501 950 | Utility issue fee (or reissue) | |
| 1502 470 | 2502 235 | Design issue fee | |
| 1503 630 | 2503 315 | Plant issue fee | |
| 1460 130 | 2460 65 | Petitions to the Commissioner | |
| 1807 50 | 2807 25 | Processing fee under 37 CFR 1.17(q) | |
| 1808 180 | 2808 90 | Submission of Information Disclosure Stmt. | |
| 1802 40 | 2802 20 | Recording each patent assignment per property (times number of properties) | |
| 1809 750 | 2809 375 | Filing a submission after final rejection (37 CFR 1.129(a)) | |
| 1810 750 | 2810 375 | For each additional invention to be examined (37 CFR 1.129(b)) | |
| 1801 750 | 2801 375 | Request for Continued Examination (RCE) | |
| 1802 900 | 2802 450 | Request for expedited examination of a design application | |
| Other fee (specify) | | | |
| Reduced by Basic Filing Fee Paid | | | |
| SUBTOTAL (3) | | | 0 |

| | | | |
|-------------------|-------------------------|-----------------------------------|------------------|
| SUBMITTED BY | | (Complete if applicable) | |
| Name (Print/Type) | Stuart A. Berger | Registration No. (Attorney/Agent) | |
| Signature | <i>Stuart A. Berger</i> | Telephone | 416-946-6341 |
| | | Date | January 21, 2003 |

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Stuart A. Berger
220 Strathearn Road
Toronto, ON M6C 1S4

January 21, 2003

The Commissioner of Patents
& Trademarks
Washington, D.C. 20231
U.S.A.


Dear Commissioner:

Re: New US Provisional Patent Application
Title: Pharmaceutical Compositions and Methods
for Treating Multidrug Resistant Cancer
Inventors: Stuart A. Berger & Yicheng Zhang

Enclosed herewith please find the following documents regarding the above new US provisional patent application that is being filed today:

- 1) Provisional Patent Application Cover Sheet;
- 2) Application Data Sheet;
- 3) Fee Transmittal;
- 4) Cheque for \$80.00 US; and
- 5) Provisional Patent Application.

Respectfully submitted,



Stuart A. Berger

Encl.

Initial Information Data Sheet

60460397 .040703

Inventor Information

Inventor One Given Name:: Stuart A.
Family Name:: Berger
Postal Address Line One:: 220 Strathearn Road
Postal Address Line Two::
City:: Toronto
State or Province:: Ontario
Postal or Zip Code: M6C 1S4
City of Residence:: [include this only if different from
postaladdress]
State of Prov. Of Residence:: [include this only if different from
postaladdress]
Country of Residence:: [include this only if different from
postaladdress]
Citizenship Country:: Canada

Inventor Two Given Name:: Yicheng
Family Name:: Zhang
Postal Address Line One:: 19B Sullivan St.
Postal Address Line Two:
City:: Toronto
State or Province:: Ontario
Postal or Zip Code: M5B 1B8
City of Residence:: [include this only if different from
postaladdress]
State of Prov. Of Residence:: [include this only if different from
postaladdress]
Country of Residence:: [include this only if different from
postaladdress]
Citizenship Country:: China

Inventor Three Given Name::
Family Name::
Postal Address Line One::
Postal Address Line Two:
City::
State or Province::
Postal or Zip Code:
City of Residence:: [include this only if different from
postaladdress]
State of Prov. Of Residence:: [include this only if different from
postaladdress]
Country of Residence:: [include this only if different from
postaladdress]
Citizenship Country::

Correspondence Information

Name Line One:: Stuart A. Berger
Name Line Two::
Address Line One:: 220 Strathearn Road
Address Line Two::
City:: Toronto
State or Province:: ON
Country:: Canada
Postal or Zip Code:: M6C 1S4
Telephone One::
Telephone Two::
Fax::
Electronic mail::

Application Information

Title Line One:: Pharmaceutical Compositions
Title Line Two:: and Methods for Treating
Title Line Three:: Multidrug Resistant Cancer
Total Drawing Sheets:: 7
Formal Drawings?: n/a
Application Type:: Prov.
Docket Number::

Representative Information

Representative Customer Number::

Continuity Information

This application is a::
> Application One::
Filing Date::

This application is a::
> Application Two::
Filing Date::

which is a::
>> Application Three::
Filing Date::
which is a::
>> Application Four::
Filing Date::

Prior Foreign Applications

Foreign Application One::
Filing Date::
Country::

Pharmaceutical Compositions and Methods for Treating Multidrug Resistant Cancer

Field of the Invention

The invention relates to pharmaceutical compositions and methods for chemotherapy.

- 5 The invention reverses multidrug resistance to chemotherapeutic agents and prevents cardiac damage caused by chemotherapeutic agents.

Background of the Invention

- Intrinsic or acquired resistance to chemotherapeutic agents is a major contributing factor to failure in cancer treatment. Clinical drug resistance often presents as a multi-drug
- 10 resistance (MDR) phenotype, characterized as *de novo* resistance to a variety of structurally diverse cytotoxic drugs or as developed cross-resistance to chemotherapeutic agents that have never been used in previous chemotherapy [17]. Although the cellular basis underlying drug resistance is not fully understood, several factors have been identified that contribute to its development. These include drug efflux mechanisms,
- 15 increased drug inactivation (e.g. glutathione-S-transferase and resistance to alkylating agents), drug target mutation (topoisomerase mutation), altered DNA repair and resistance to apoptosis (p53 mutation, bcl-2 overexpression etc.) [1]. Clinical drug resistance may be caused by any one or a combination of these mechanisms. Increased transmembrane efflux of xenobiotics is one of the best characterized mechanisms of
- 20 MDR and is known to be mediated through over-expression of adenosine triphosphate (ATP)-binding cassette (ABC) transporter superfamily members such as P-glycoprotein (P-gp / MDR1), multidrug resistance associated protein (MRP1), or breast cancer

resistance protein (BCRP) [5, 14, 19, 20]. P-gp, the most extensively studied of these transporters, is encoded by the *mdr1* gene and found to be overexpressed in many tumor cells that are resistant to anthracyclines or vinca alkaloids. Transfection of the *mdr1* gene to drug-sensitive cell lines can transfer the MDR phenotype [28]. In about 30-40% of
5 primary and more than 50% of metastatic breast cancer patient samples, P-gp was overexpressed [16, 27]. Increased expression of P-gp correlates with adverse prognosis and is associated with poor chemotherapy response and overall survival [27].

The prognostic importance of P-gp overexpression shows that the ability to prevent or reverse multi-drug resistance would be clinically valuable. This has led to the
10 identification of a wide variety of compounds that are capable of reversing MDR through the inhibition of P-gp. Preclinical *in vitro* and *in vivo* studies in mice using MDR reversing agents such as verapamil, quinidine and cyclosporine A have demonstrated enhanced anti-MDR tumor activity [9]. To date, clinical trials have been conducted to evaluate the efficacy of MDR reversing agents with mixed results. In some cases, serum
15 levels of reversing agents needed to block Pgp could not be achieved. In other cases, Pgp could be blocked but the levels of chemotherapeutic drugs had to be reduced in order to prevent excessive toxicity. However, some small scale studies in P-gp positive AML and VAD-refractory multiple myeloma showed that incorporation of verapamil or cyclosporin in chemotherapy significantly improved overall survival [6, 18, 26]. New, more potent P-
20 gp inhibitors such as PSC388, GF120918, dexverapamil and XR9576 are also currently being evaluated in clinical trials and to date, preliminary results indicate that at minimum, it is possible to obtain serum levels of reversing agents sufficient to block P-gp [22, 24]. However, there remains a need for compositions that more effectively prevent multi-drug

resistance. As *mdr1/P-gp* is also expressed in certain normal tissues, blockade of *P-gp* *in vivo* by reversal drugs inevitably changes drug distribution and metabolism, thus altering the pharmacokinetics of chemotherapeutic agents. As a result, increased accumulation of the drugs in plasma or tissue can cause increased toxicity (Table 1).

5

TABLE 1: Cardiotoxicity of chemotherapy

| Drug | Toxic dose range ^a | Toxicity |
|------------------|--|---|
| Amisacrine | Conventional dose | Ventricular arrhythmia |
| Busulfan | Oral daily dose | Endocardial fibrosis |
| Cisplatin | Conventional dose | Acute myocardial ischemia |
| Cyclophosphamide | > 100-120 mg/kg over 2 d | Congestive heart failure, hemorrhagic myocarditis/pericarditis/necrosis |
| Dactinomycin | > 550 mg/m ² (total dose) | Same toxicity as doxorubicin |
| Doxorubicin | > 550 mg/m ² (total dose) | Congestive heart failure (cumulative toxic effect), arrhythmias |
| | < 550 mg/m ² (total dose) | Cardiac toxicity in the presence of additional risk factors |
| Fluorouracil | Conventional dose | Anginal/myocardial infarction |
| Interferons | Conventional dose | Exacerbation of underlying cardiac disease |
| Interleukin-2 | Conventional dose | Acute myocardial injury, ventricular arrhythmia, hypotension |
| Mitomycin | Conventional dose | Myocardial damage similar to radiation-induced injury |
| Mitoxantrone | > 100-140 mg/m ² (total dose) | Congestive heart failure, decreased left-ventricular ejection fraction |
| Paclitaxel | Conventional dose | Bradycardia |
| Vinblastine | Conventional dose | Myocardial infarction |
| Vincristine | Conventional dose | Myocardial infarction |

^a Route of administration is IV unless otherwise indicated. Conventional dose is commonly accepted therapeutic range.

Adapted, with permission, from Grever MR, Grieshaber CK: Toxicology by organ system. In Holland JF et al (eds): *Cancer Medicine*, 4th ed, p 477. Baltimore, Williams & Wilkins, 1992.

Doxorubicin, one of the most potent chemotherapeutic agents for treating hematological malignancies and solid tumors, has dose-limiting cardiotoxicity both in animal models

and in cancer patients. In one study, Coadministration of cyclosporin and doxorubicin resulted in 55% and 350% increase of area-under-the-curve (AUC) of doxorubicin and its metabolite doxorubicinol respectively (Bartlett, 1994). PSC388, when used in combination with doxorubicin, increased doxorubicin AUC by 10 -fold [12]. Using a murine model, Sridhar showed that the combination of verapamil and doxorubicin increased peak doxorubicin concentration in heart tissue by about 40% compared to doxorubicin alone. This increased tissue doxorubicin level led to severe heart damage and significantly lower survival rate [25]. There is a need for compositions and methods for chemotherapy which do not cause heart damage. The need applies to the most common chemotherapy drugs, such as those shown in Table 2.

Table 2. Cytotoxic drugs which are transported by P-gp.

| | | |
|----|-----------------------|------------------------|
| | Anthracyclines | Vinca Alkaloids |
| 15 | Doxorubicin | Vincristine |
| | Daunorubicin | Vinblastine |
| | Idarubicin | Vinorelbine |
| | Epirubicin | Others |
| | Epipodophyllotoxins | Mitoxantrone |
| 20 | Etoposide | Dactinomycin |
| | Teniposide | Amsacrine |
| | Taxanes | Trimetrexate |
| | Paclitaxel | Mitomycin |
| | Docetaxel | Mithramycin |
| 25 | | |

Summary of the Invention

The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i)

circumventing or treating multi-drug resistance in a subject or ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject. The invention also includes kits containing these compositions and methods of use of these pharmaceutical compositions. In variations of the invention, mitoxantrone, VP-16 and vinblastine, or
5 analogs thereof, are useful in the compositions and methods of the invention in place of doxorubicin. Other useful compounds which are subject to P-gp-mediated efflux (preferably those compounds in the same class that have similar activities as doxorubicin, mitoxantrone, VP-16 and vinblastine and which do not cause cause cardiotoxicity) are described below. We also use ketotifen and its analogs or compounds such as cetirizine
10 and mizolastine with chemotherapy drugs described in this application (or analogs thereof).

The invention relates to a method for treating cancer, comprising stimulating cancer cells with a composition that is a Ca^{2+} -mobilizing agonist while concurrently blocking Ca^{2+} influx, whereby the cancer cells are sensitized to cell death induction. Ketotifen is a first
15 generation antihistamine with store-operated Ca^{2+} channel antagonist properties [10]. As a calcium influx blocker, it was previously demonstrated that ketotifen could induce cell death in an activation-enhanced manner in leukemia cells [13], mast cells [23], and breast cancer cells [29]. In the course of evaluating the ability of ketotifen to induce cell death in breast cancer cells, it was observed that ketotifen could sensitize multi-drug resistant
20 human breast cancer cells to doxorubicin. The invention shows that ketotifen can reverse multi-drug resistance through inhibition of P-gp. More importantly, it shows that ketotifen also reduces cardiotoxicity caused by high dose doxorubicin *in vivo* thus uniquely identifying ketotifen as both a MDR-reversing and cardioprotective agent.

- Ketotifen restores sensitivity of P-glycoprotein-overexpressing, multi-drug resistant, MCF-7/adr cells to doxorubicin, mitoxantrone, VP-16 and vinblastine. *In vivo*, it was demonstrated that pretreatment of mice with ketotifen caused an increased accumulation of doxorubicin in cardiac tissue, consistent with a block in drug clearance. However, it
- 5 was also observed that unlike verapamil, ketotifen pre-treatment did not enhance doxorubicin toxicity but in fact provided protection, both at the level of cardiac tissue damage and in survival. The invention provides the surprising invention that ketotifen reverses multi-drug resistance due to P-glycoprotein overexpression and provides cardioprotection to doxorubicin.
- 10 Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the
- 15 art from this detailed description.

Brief Description of the Drawings

Preferred embodiments of the invention will be described in relation to the drawings in which:

- 20 Fig.1 Dose response curve of ketotifen and verapamil as MDR reversal compounds. MCF-7/adr cells were treated with different concentrations of reversal compounds with or without 2 μ M doxorubicin for 24 hours. Cells were harvested , and plated for growth of breast cancer colonies in triplicates. The data are presented as perent of control clonogenicity in the absence of drug ($p < 0.0001$). DXN: doxorubicin.

Fig.2 Influence of 10 μ M of ketotifen on the toxicities of four cytotoxic drugs. MCF-7/adr cells were treated with different concentrations of chemotherapeutic agents in the presence or absence of 10 μ M ketotifen for 24 hours. Cells were harvested, washed and plated for growth of breast cancer colonies as described in the Materials and Methods.

5 The data are presented as percent of control clonogenicity in the absence of drug (p<0.0001). Ke: ketotifen.

Fig.3 Ketotifen fails to reverse MDR of MCF-7/mx and MCF-7/vp cell lines. MCF-7/mx and MCF-7/vp cell lines were treated and assayed as described in Figs. 1 and 2. The
10 toxicities of mitoxantrone and Vp-16 were evaluated respectively in MCF-7/mx and MCF-7/vp cells. Ke: ketotifen.

Fig.4 Flow Cytometric analysis of intracellular doxorubicin retention. MCF-7/adr cells (5x10⁵/ml) were incubated with 2 μ g/ml of doxorubicin at 37°C for 2.5 hours in the presence of different concentrations of ketotifen or verapamil. Cells were washed and
15 resuspended in ice-cold PBS. Doxorubicin relative fluorescence was measured by flow cytometry. A: 0 μ M, b: 2 μ M, c: 10 μ M ketotifen or verapamil.

Fig.5 Doxorubicin accumulation in heart tissue. Mice were treated with i.p. injection of several agents ketotifen or verapamil, followed 30 minutes later by 15mg/kg doxorubicin or saline (as control). Three hours following injection of doxorubicin, three
20 mice were sacrificed in each group and the hearts were excised, rinsed, minced and homogenated. The tissue doxorubicin was extracted with ice-cold acid ethanol solution (0.3N HCl in 50% ethanol). The doxorubicin in the supernatants was measured by

fluorescence spectrometry. DXN: doxorubicin, VPL: verapamil, Ke: ketotifen. **:

p<0.01.

Fig.6 Histological evaluation of cardiotoxicity. Mice were injected with reversal compounds ketotifen (25mg/kg) or verapamil (25mg/kg) followed by doxorubicin

5 (15mg/kg). Three mice in each group were sacrificed 4 days post treatment. The hearts were removed and fixed in 10% formalin. At least 3 sections were made and stained with H.E.. Slides were evaluated by light microscopy (original magnification = 400X). In mice receiving doxorubicin alone, some capillary dilation, degeneration and vacuolization can be readily observed. Combination of verapamil with doxorubicin aggravates these
10 manifestations of cardiotoxicities especially the cytoplasmic vacuolization. Ketotifen, on the other hand, alleviates these pathological changes induced by doxorubicin.

Fig.7 Modulation of doxorubicin toxicity by verapamil or ketotifen. Mice were injected with reversal compounds ketotifen (25mg/kg) or verapamil (25mg/kg) followed by doxorubicin (15mg/kg). Mice were observed for survival for 30 days following treatment.

15 ***: p<0.001

Detailed Description of Invention

The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i)
20 circumventing or treating multi-drug resistance in a subject and ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject. The anthracycline protective effects and reversal of MDR were unknown prior to this invention.

The invention also includes a kit comprising the agents i) ketotifen or an analog thereof and ii) doxorubicin, and ~~directions~~ for administering i) and ii) to a subject, preferably for

administering the agents to treat cancer, i) prevent or treating multi-drug resistance in a subject or ii) prevent doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject.

5 The invention also includes a method for treating cancer in a subject, comprising administering to the subject the pharmaceutical composition of the invention or the agents of the kit of the invention. The cancer can be a solid tumor or a hematological malignancy.

10 The invention also includes a method for i) circumventing or treating multi-drug resistance in a subject or ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject, comprising administering to the subject the pharmaceutical composition of claim 3.

A preferred embodiment of the invention includes a method for treating cancer in a subject, including

15 administering to the subject an effective amount of ketotifen or an analog thereof, and

administering to the subject an effective amount of doxorubicin or an analog thereof.

20 Preferably, the ketotifen is administered prior to the doxorubicin, more preferably at least 30 minutes prior to the doxorubicin. In the methods, the ketotifen or analog thereof and doxorubicin or analog thereof are preferably administered orally, intravenously, intraperitoneally, subcutaneously or rectally or by a combination of more than one of the foregoing.

Ketotifen

25 Ketotifen has the chemical name 4-(1-Methyl-4-piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b] thiophen-10(9H)-one hydrogen fumarate and the molecular formula $C_{23}H_{23}NO_5S$ (Chemical Abstracts Registry Number for Ketotifen is 34580-13-7). It is described, for example, in U.S. Pat. Nos. 3,682,930, 3,749,786, and 5,399,360. Examples of ketotifen analogs are found in U.S. Pat. Nos. 3,682,930 and 3,749,786. The

preferred ketotifen analogs are those which are suitable for use in mammals, such as humans. Methods which may be employed in screening and identifying useful ketotifen analogs and derivatives are described, for example, in U.S. Pat. No. 3,749,786.

Doxorubicin

- 5 Doxorubicin has the chemical name 8*S*,10*S*)-10-[(3-amino-2,3,6-trideoxy- α -*L*-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride. The molecular formula of the drug is $C_{27}H_{29}NO_{11} \cdot HCl$ and its analogs are also known in the art. Analogs include mitoxantrone, daunorubicin, and N-acetyl daunorubicin. Other doxorubicin analogs are described in US Patent Nos.
- 10 4,672,057, 4,345,068, 4,314,054, 4,229,355, 4,216,157, 4,199,571, 4,138,480.

Other compounds are described below. Preferred compounds and analogs have at least 25%, 50%, more preferably at least 75% of the activity of doxorubicin and ketotifen for reversing MDR without cardiotoxicity. Activity may be measured by a MDR assay or cardioprotection study as described in this application.

- 15 "Preventing" or "Reversing" drug resistance means inhibiting P-gp to circumvent, reduce or avoid MDR. It does not necessarily mean modifying the cancer cells so that they no longer have the MDR phenotype of overexpressed P-gp.

Pharmaceutical Compositions

- The above described substances may be formulated into pharmaceutical compositions for
- 20 administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals. Compositions for chemotherapy are described in *Cancer*
- 25 *Chemotherapy Handbook* by David S. Fischer, et al. (5th Ed., Mosby-Year Book, Inc.

Publication date, May, 1997); *Lippincott's Cancer Chemotherapy Handbook* by Delia C. Baquiran, Jean Gallagher (Lippincott Williams and Wilkins Paperback); Physician's

Cancer Chemotherapy Drug Manual, 2002 and CD-ROM by Edward Chu, Vincent T. Devita (2002, Jones & Bartlett Pub)

Administration of a therapeutically active amount of pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time
5 necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance to elicit a desired response in the individual. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may
10 be proportionally reduced as indicated by the exigencies of the therapeutic situation.

An active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, rectal administration, inhalation, or transdermal application. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids
15 and other natural conditions which may inactivate the compound.

The compositions described herein can be prepared by *per se* known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example,
20 in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985) or Handbook of Pharmaceutical Additives (compiled by Michael and Irene Ash, Gower Publishing Limited, Aldershot, England (1995)). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or
25 diluents, and may be contained in buffered solutions with a suitable pH and/or be iso-osmotic with physiological fluids.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples. These

examples are described solely for the purpose of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances might suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

Ketotifen specifically reverses MDR mediated by P-gp transporter.

The toxicity of the cytotoxic drugs was measured by clonogenicity assay. As shown in Fig. 1A, significant dose-dependent reversal of doxorubicin resistance was observed with ketotifen. Beginning at 1 μ M, ketotifen restored doxorubicin toxicity while at 10 μ M, the MDR phenotype of MCF-7/adr cells was completely reversed. Over this concentration range, ketotifen itself is non-toxic to MCF-7/adr cells. The ability of ketotifen to restore sensitivity of MCF-7/adr cells to doxorubicin was compared with verapamil. As shown in Figs. 1A and 1B, both ketotifen and verapamil reverse resistance at similar concentrations. MCF-7/adr cells are also relatively resistant to mitoxantrone, VP-16 and vinblastine. As shown in Fig. 2, the sensitivity to these drugs was also restored by 10 μ M ketotifen. The IC_{90} s of different cytotoxic drugs were calculated from dose-response curves for MCF-7/adr or MCF-7/wt cells in the presence or absence of 10 mM of ketotifen. As summarized in Table 3, IC_{90} levels on MCF-7/adr cells in the presence of ketotifen are almost identical to those for parental MCF-7 cells. In contrast to its reversing activity on MCF-7/adr cells, ketotifen influenced neither the toxicity of mitoxantrone on MCF-7/mx nor the toxicity of VP-16 on MCF-7/vp cells (Fig. 3). These two cell lines exhibit the MDR phenotype by overexpressing BCRP [19] and MRP

transporters [21] respectively. Thus, ketotifen is a specific reversing agent for MDR associated with P-gp.

Table 3. IC₉₀ (μM) of cytotoxic drugs on MCF-7/wt and MCF-7/adr

| | MCF-7/wt | MCF-7/adr | |
|----------------|----------|-----------|------|
| | | -ke | +ke |
| 5 Doxorubicin | 0.12 | >10 | 0.18 |
| Mitoxantrone | 0.01 | 0.22 | 0.02 |
| VP-16 | 17 | 220 | 20 |
| 10 Vinblastine | 0.8 | 410 | 1.2 |

Increased intracellular retention of doxorubicin in ketotifen treated MCF-7/adr cells.

Most MDR reversing agents act by inhibiting the transporting activity of P-gp. In order to
 15 determine if ketotifen inhibits P-gp activity, the intrinsic fluorescence of doxorubicin was
 used as a marker and measured drug accumulation by flow cytometry. MCF-7/adr cells
 pretreated with ketotifen or verapamil were exposed to doxorubicin and fluorescence was
 measured. As shown in Fig. 4, in the presence of either verapamil or ketotifen,
 fluorescence from doxorubicin increased in the pre-treated cells. 2 μM of ketotifen
 20 increased relative fluorescence by 50%, while 10 mM of ketotifen nearly doubled the
 fluorescence intensity. This result shows that ketotifen causes an accumulation of
 doxorubicin in MCF-7/adr cells and that ketotifen mediates its reversal ability through the
 inhibition of drug efflux.

Tissue doxorubicin concentrations in the heart.

25 To determine the interactions of ketotifen with cytotoxic drugs *in vivo*, mice were given
 i.p. injections of reversal agent, followed by 15 mg/kg doxorubicin. Tissue concentrations

of doxorubicin were determined by measuring doxorubicin fluorescence in heart tissue following different time periods after injection. The 3-hour time point values in different groups were compared as this point was the peak concentration was observed. As observed with verapamil, pre-treatment of mice with ketotifen significantly increased doxorubicin accumulation in the heart in comparison to control (72 ± 5 vs 36 ± 3 ng/mg protein, $p < 0.01$, Fig.5). This result shows that like verapamil, ketotifen causes a buildup of doxorubicin in tissue, likely due to inhibition of normal drug clearance mechanisms [25].

Ketotifen prevents cardiac tissue damage.

- Cardiac tissue damage caused by anthracyclines is well known and characterized by cardiac hypertrophy, vacuolization disruption of myofibrils and cell loss [3]. In order to characterize the effect of combined MDR reversing agent plus doxorubicin treatment on heart tissue, mice were treated with ketotifen or verapamil followed by doxorubicin. Four days later, heart tissue was fixed, sectioned and stained with hematoxylin and eosin. As shown in Fig 6, mice treated with doxorubicin alone demonstrated well known pathological changes including dilation of capillaries, myocyte degeneration and vacuolization in left ventricular tissue (Fig. 6B). Addition of verapamil enhanced cardiac damage caused by doxorubicin (Fig.6C). In contrast, heart tissue from mice pre-treated with ketotifen (25mg/kg) 30 minutes before doxorubicin had observable decreases in the extent of cardiac damage (Fig.6D) with less cell drop-out, maintenance of myofibril structure and less vacuolization.

Cardiotoxicity and survival.

Since cardiac damage is reduced in mice receiving ketotifen plus doxorubicin, it was shown that the addition of ketotifen enhances mouse survival. Mice were pre-treated with ketotifen or verapamil, followed by a single treatment with doxorubicin and followed the animals over 5 weeks. Animals were sacrificed when they showed signs of lethargy or distress. As shown in Fig. 7, the survival rate of mice receiving doxorubicin plus verapamil was significantly lowered comparing to those mice treated with doxorubicin alone. For the doxorubicin plus verapamil group, survival rate at day 30 was 0% with, median survival time of 12.3 days while 42% of the doxorubicin alone group survived 30 days post treatment with a median survival of 19.3 days ($p < 0.001$). In contrast, pre-treatment of mice with ketotifen led to extended survival compared to doxorubicin alone with 57% survival rate at day 30 and a median survival time of 23.2 days ($p < 0.001$ compared to Dox + Verapamil). Since prolongation of survival in mice treated with ketotifen plus doxorubicin correlated with the protection of ketotifen on the cardiotoxicity induced by doxorubicin, these results clearly show that ketotifen enhances survival due to cardioprotection.

In this study, it was shown that the antihistamine ketotifen can reverse multi-drug resistance in MCF-7/adr cells through inhibition of P-gp. This effect is specific in that cells overexpressing BCRP or MRP are not affected by ketotifen. At high concentrations, ketotifen also blocks store-operated Ca^{2+} influx and induces activation enhanced cell death [13, 29]. However, ketotifen's P-gp-inhibitory activity appears to be unrelated to its Ca^{2+} channel blocking activity since the concentrations required for P-gp inhibition are much lower. Furthermore, it was observed that Ca^{2+} ionophores have no effect on the ability of ketotifen to reverse MDR (Zhang and Berger; unpublished), providing

additional evidence that ketotifen's MDR reversing activity is unrelated to its Ca^{2+} channel antagonism. It was further shown that pretreatment with ketotifen caused an increased accumulation of doxorubicin in mouse cardiac tissue, consistent with a block in drug clearance. However, unlike verapamil, ketotifen did not enhance doxorubicin toxicity but in fact provided protection, both at the level of cardiac tissue damage and in survival. These observations therefore show that ketotifen is unique in its ability to both reverse multi-drug resistance due to P-glycoprotein overexpression and provide cardioprotection to doxorubicin.

Although the mechanism of cardiotoxicity caused by anthracyclines is not fully understood, it is generally believed that highly active reactive oxygen species (ROS) triggered by anthracycline metabolites may play a central role in the initiation of a series of reactions leading to myocyte damage [11, 15]. While antioxidants have shown some promise as cardioprotective agents *in vitro* and in animal models, clinical trials have not yet provided consistent benefit [4, 8]. Furthermore, the concern arises that the systemic application of antioxidants may also limit the anti-tumor efficacy of doxorubicin.

Previous studies investigating the role of mast cell activation products in anthracycline-mediated cardiotoxicity had demonstrated that ketotifen could reduce doxorubicin cardiotoxicity and improve overall survival in a murine model [2]. In another study, doxorubicin was shown to induce mast cell degranulation and histamine release, consistent with a role for mast cell activation in enhancing cardiac damage [7]. The invention shows the protective effect of ketotifen. Ketotifen's beneficial effect on survival can be partly attributed to cardiac protection based on the observed decrease in severity of cardiac damage in mice pre-treated with ketotifen.

The clinical use of anthracyclines is limited by its cardiotoxicity. Furthermore, schemes employing multi-drug reversing agents typically require reductions in chemotherapeutic dose due to inhibition of drug clearance mechanisms. The observations showing ketotifen as a multi-drug reversing agent with cardioprotective activity shows that this
5 unique combination of properties is clinically useful in the control of multi-drug resistant tumors.

Materials and Methods

Human Breast Cancer Cell Lines and Culture Conditions.

MCF-7 (MCF-7/wt) and its multidrug resistant variant MCF-7/adr cells were used. MCF-
10 7/mx and MCF-7/vp cell lines were also used. Other cell lines could also be used. MCF-7/mx cell line was generated through selection in vitro with mitoxantrone and overexpresses Breast Cancer Resistance Protein (BCRP) [19]. The MCF-7/vp cell line was selected with etoposide and overexpresses Multidrug Resistance-associated Protein gene (MRP) [21]. All the cell lines were grown routinely as monolayer culture in
15 Dulbecco's Minimal Essential Media (DMEM) supplemented with L-glutamine (2mM), penicillin, streptomycin and 10% heat-inactivated fetal bovine serum (FBS, GIBCO) in an atmosphere of 5% CO₂ at 37°C. The cell lines were passaged weekly.

Chemicals.

Ketotifen, verapamil and all the chemotherapeutic agents (doxorubicin, etoposide VP-16,
20 vinblastine and mitoxantrone) were purchased from Sigma Chemical Co. (St. Louis, MO). Ketotifen was freshly dissolved in DMSO before use, diluted with culture medium and added to the plate at the indicated concentrations. The final concentration of solvent

DMSO was always less than 0.1%. All the other drugs were dissolved either in DMSO (VP-16 and vinblastine) or saline and stored at -20°C as stock solutions.

Drug treatments and breast cancer clonogenic assay.

Exponentially growing MCF-7/wt and its three mutants MCF-7/adr, MCF-7/mx and
 5 MCF-7/vp were trypsinized, washed with fresh medium and plated in 6-well plates at a density of 1×10^5 /ml. Cytotoxic drugs of different concentrations were applied to cells in the presence or absence of ketotifen or verapamil for 24 hours. Both adherent and non-adherent cells were collected and washed with fresh medium. Cell aliquots (5×10^3) were plated in 1ml of 0.3% agar over 1 ml of 0.5% agar underlayer prepared in IMDM
 10 containing 10% horse serum (GIBCO). The upper layer consisted of 20% FBS, 10 μ g/ml of bovine insulin, 2.5 mg/ml of hydrocortisone, 5×10^{-7} M of 17- β -estradiol (Sigma) and 50 ng/ml of EGF (R & D Systems). Colonies larger than 50 μ m in size were scored after 14 days of incubation at 37°C in a humidified atmosphere of 5% CO₂ in air.

Flow cytometry.

15 As doxorubicin itself is a fluorescent substance, the doxorubicin content in MCF-7/adr cells can be measured with flow cytometry. Briefly, cells (5×10^5 /ml) were incubated with 2 μ g/ml of doxorubicin at 37°C for 2.5 hours with or without reversal agents, washed and resuspended in ice-cold PBS. Doxorubicin fluorescence was measured by flow cytometry using a FACStar Plus flow cytometer (FL2, emission at > 570nm, Becton Dickinson). 10⁴
 20 cells were analysed for each sample.

Animals and in vivo treatment.

- Female Balb/c mice (8-10 weeks of age, 20-22 g of body weight) were purchased from Jackson Laboratory (Maine, USA). Protocols were approved by the Animal Care Committee of the University Health Network. Animals were divided into 6 groups of 15 to 20 mice each and received drug treatments as follows: saline, ketotifen 25mg/kg, verapamil 25mg/kg, doxorubicin 15mg/kg plus saline, doxorubicin 15mg/kg plus ketotifen 25mg/kg, doxorubicin 15mg/kg plus verapamil 25 mg/kg. All the treatments were administered via i.p. After treatment, mice were kept in sterile environment for six to eight weeks. Acute toxicities and survival was observed for different treatment groups. Mice were sacrificed when they displayed lethargic behaviour or any signs of distress.
- 10 Three mice from each group were sacrificed on day 4- post treatment. Hearts were removed immediately and fixed in 10% neutral buffered formalin. Tissue sections were made from heart tissue and stained with hematoxylin and eosin or with 1% Toluidine blue to identify mast cells. All the slides were evaluated by light microscopy for cardiac damage, mast cell density and degranulation.
- 15 *Doxorubicin concentrations in heart tissues.*
- 3 to 5 mice in each group were treated with the same drug combinations used for survival. Three hours following injection of doxorubicin, mice were sacrificed. Doxorubicin concentrations in heart tissues were determined by fluorometric detection of doxorubicin using the method of Sridhar [25]. Briefly, hearts were excised immediately, 20 rinsed with ice cold normal saline, minced with scissors, and homogenized in ice cold ethanol- acid solution (0.3 N HCl in 50% ethanol) using a Polytron homogenizer. The homogenates were centrifuged at 20,000 g for 20 minutes at 4°C. Fluorescence of the supernatants was measured using a Tecan Spectrafluor (excitation wavelenth of 468,

emission wavelenth of 590, Hewlett Packard). The doxorubicin standard curve was made by mixing known amounts of doxorubicin with heart tissue and processed using an identical protocol. The fluorescence of supernatant from cardiac tissue without doxorubicin served as background. The concentration of doxorubicin was normalized to
5 total protein content of the same tissue.

Statistical analysis.

All the colony data were analyzed by two-way analysis of variance (ANOVA), with differences between individual means determined by Bonferroni's post-tests. Data were expressed as means \pm SEM. The Kaplan-Meier estimate was used to determine
10 differences in the survival periods for mice following different drug combination treatments.

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover
15 various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in
20 its entirety.

References

1. Arceci RJ (2000) Can multidrug resistance mechanisms be modified? *Br J Haematol* 110: 285
- 5 2. Bartoli Klugman F, Decorti G, Candussio L, Mallardi F, Grill V, Zweyer M, Baldini L (1988) Effect of ketotifen on adriamycin toxicity: role of histamine. *Cancer Lett* 39: 145
3. Birtle AJ (2000) Anthracyclines and cardiotoxicity. *Clin Oncol* 12: 146
4. Blatt J (1997) ICRF-187 as a cardioprotectant in children treated with
10 anthracyclines. *Pediatr Hematol Oncol* 14: iii
5. Cole SP, Deeley RG (1998) Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. *Bioessays* 20: 931
6. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD (1995) A phase III randomized study of oral verapamil as a
15 chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. *Cancer* 75: 815
7. Decorti G, Candussio L, Klugmann FB, Strohmayer A, Mucci MP, Mosco A, Baldini L (1997) Adriamycin-induced histamine release from heart tissue in vitro. *Cancer Chemother Pharmacol* 40: 363
- 20 8. Dorr RT (1996) Cytoprotective agents for anthracyclines. *Semin Oncol* 23: 23
9. Ford JM (1995) Modulators of multidrug resistance. Preclinical studies. *Hematol Oncol Clin North Am* 9: 337

10. Franzius D, Hoth M, Penner R (1994) Non-specific effects of calcium entry antagonists in mast cells. *Pflugers Archiv European Journal of Physiology* 428: 433
- 5 11. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochem Pharmacol* 57: 727
- 10 12. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJ, Eeltink C, Vermorken JB, Pinedo HM (1997) A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. *Clin Cancer Res* 3: 2005
13. Gommerman JL, Berger SA (1998) Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. *Blood* 91: 1891
14. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem* 62: 385
- 15 15. Horenstein MS, Vander Heide RS, L'Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. *Mol Genet Metab* 71: 436
16. Lehnert M (1998) Chemotherapy resistance in breast cancer. *Anticancer Res* 18: 2225
- 20 17. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. *Cancer Chemother Pharmacol* 40: S3
18. Mross K, Bohn C, Edler L, Jonat W, Queisser W, Heidemann E, Goebel M, Hossfeld DK (1993) Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. *An AIO clinical*

trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.

Ann Oncol 4: 45

19. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M,
Greenberger L, Cole SP, Doyle LA (1999) Atypical multidrug resistance: breast
5 cancer resistance protein messenger RNA expression in mitoxantrone-selected
cell lines. J Natl Cancer Inst 91: 429
20. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen
TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, et al. (1993)
Overexpression of a M(r) 110,000 vesicular protein in non-P- glycoprotein-
10 mediated multidrug resistance. Cancer Res 53: 1475
21. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH (1994) Multidrug
resistance-associated protein gene overexpression and reduced drug sensitivity of
topoisomerase II in a human breast carcinoma MCF7 cell line selected for
etoposide resistance. Cancer Res 54: 152
- 15 22. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G (1997)
Modulation and prevention of multidrug resistance by inhibitors of P-
glycoprotein. Cancer Chemother Pharmacol 40: S13
23. Soboloff J, Berger SA (2002) Sustained ER Ca²⁺ depletion suppresses protein
synthesis and induces activation-enhanced cell death in mast cells. J Biol Chem
20 277: 13812
24. Spicer D, Arzoo K, Groshen S (2000) Valspodar +paclitaxel in advanced breast
cancer: A California Cancer Consortium Phase II randomized trial. 19: 179a

25. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P, Engineer FN (1992) Effects of verapamil on the acute toxicity of doxorubicin in vivo. *J Natl Cancer Inst* 84: 1653
26. Tan B, Piwnica-Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. *Curr Opin Oncol* 12: 450
27. Trock BJ, Leonessa F, Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. *J Natl Cancer Inst* 89: 917
28. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. *Proc Natl Acad Sci U S A* 84: 3004
29. Zhang Y, Crump M, Berger SA (2002) Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using Activation Enhanced Cell Death. *Breast Cancer Research and Treatment* 72: 265

We claim:

1. A pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) doxorubicin or an analog thereof.
- 5 2. A pharmaceutical composition for use in treating cancer comprising i) ketotifen or an analog thereof and ii) doxorubicin or an analog thereof.
3. A pharmaceutical composition for use in i) preventing or treating multi-drug resistance in a subject or ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject, comprising an effective amount of ketotifen or an analog thereof.
- 10 4. A kit comprising the agents i) ketotifen or an analog thereof and ii) doxorubicin, and directions for administering i) and ii) to a subject .
5. The pharmaceutical composition of claim 1 or 2 or the kit of claim 4, comprising the ketotifen, doxorubicin or analog thereof in an oral, intravenous, intraperitoneal, subcutaneous or rectal dosage form or in combination of the foregoing dosage forms.
- 15 6. A method for treating cancer in a subject, comprising administering to the subject the pharmaceutical composition of claim 1 or 2 or the agents of the kit of claim 4.
7. The method of claim 6, wherein the cancer comprises a solid tumor or a hematological malignancy.
- 20 8. A method for i) preventing or treating multi-drug resistance in a subject or ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject, comprising administering to the subject the pharmaceutical composition of claim 3.
9. A method for treating cancer in a subject, comprising
administering to the subject an effective amount of ketotifen or an analog thereof,
25 and

administering to the subject an effective amount of doxorubicin or an analog thereof.

10. The method of claim 9, wherein the ketotifen is administered prior to the doxorubicin.
11. The method of claim 10, wherein the ketotifen is administered at least 30 minutes
5 prior to the doxorubicin.
12. The method of any one of claims 7 or 9 to 11 wherein the ketotofin or analog thereof and doxorubicin or analog thereof are administered orally, intravenously, intraperitoneally, subcutaneously or rectally or by a combination of more than one of the foregoing.
- 10 13. The use of the pharmaceutical composition of claim 1 or 2 or the agents of the kit of claim 4 for treating cancer in a subject.
14. The use of the pharmaceutical composition of claim 3 for i) preventing or treating multi-drug resistance in a subject or ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject in a subject.
- 15 15. The use of ketotifen and doxorubicin for preparation of a medicament for treatment of cancer.
16. The use of claim 13 or 15, wherein the cancer comprises a solid tumor or a hematological malignancy.
17. A method of determining whether cancer should be treated with ketotifen or an analog
20 thereof and doxorubicin or an analog thereof, comprising determining whether P-gp is overexpressed by the cell.
18. The method of claim 17, wherein the cancer comprises a solid tumor or a hematological malignancy.
19. The method of claim 17, further comprising treating the cancer with ketotifen or an
25 analog thereof and doxorubicin or an analog thereof.
20. A method for i) preventing or treating multi-drug resistance in a subject or ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject, comprising administering to the subject a compound having MDR-reversing

and anthracycline-protective activity.

Abstract

The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) doxorubicin or an analog thereof. The pharmaceutical composition
 5 is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or treating multi-drug resistance in a subject or ii) preventing doxorubicin or doxorubicin analog induced cardiac tissue damage in a subject.





Figure 2



60445357, 040702

Figure 3




Figure 4






Figure 5




60460397, 040703


DXN



DXN+Ke



Control



DXN+VPL



Figure 6

60460397 .040703




Figure 7

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.